Cipher Pharmaceuticals Sets March Date for Q4 and Fiscal 2025 Results

Cipher Pharmaceuticals ( (TSE:CPH) ) has shared an update.

Cipher Pharmaceuticals Inc. will release its fourth-quarter and full-year 2025 financial results after markets close on March 12, 2026, followed by a conference call the next morning to review earnings and recent corporate developments. The scheduled disclosure will give investors and analysts an updated view on the specialty drug maker’s performance and strategic progress as it advances its portfolio of products targeting unmet medical needs in North and South American markets.

The most recent analyst rating on (TSE:CPH) stock is a Buy with a C$20.00 price target. To see the full list of analyst forecasts on Cipher Pharmaceuticals stock, see the TSE:CPH Stock Forecast page.

Spark’s Take on TSE:CPH Stock

According to Spark, TipRanks’ AI Analyst, TSE:CPH is a Outperform.

The score is driven primarily by strong financial performance (notably cash flow quality, profitability, and reduced leverage). Earnings-call takeaways reinforce the strength via Natroba-led growth and debt repayment, while technical indicators are modestly positive. Valuation appears reasonable, but the lack of dividend yield data and headwinds in licensing/Absorica temper the overall rating.

To see Spark’s full report on TSE:CPH stock, click here.

More about Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and development-stage products. The company focuses on acquiring therapies that address unmet medical needs, steering them through clinical development and regulatory approval, and marketing them across Canada, the U.S. and South America.

Average Trading Volume: 26,948

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$377.8M

See more insights into CPH stock on TipRanks’ Stock Analysis page.